Month: May 2013

May 6, 2013
Another one bites the dust

Bad news for Bayer this week. The company has just announced the discontinuation of a Phase II/III trial evaluating the efficacy and safety of BAY 86-6150 in people with hemophilia A and hemophilia B with inhibitors. It was hoped that the product, a recombinant factor VIIa (rFVIIa) protein, would reduce the dosing frequency as compared …

Read article